These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25382190)

  • 1. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
    Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
    Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside.
    Avan A; Maftouh M; Funel N; Ghayour-Mobarhan M; Boggi U; Peters GJ; Giovannetti E
    Curr Med Chem; 2014; 21(8):975-89. PubMed ID: 23992325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
    Bahrami A; Shahidsales S; Khazaei M; Ghayour-Mobarhan M; Maftouh M; Hassanian SM; Avan A
    J Cell Physiol; 2017 Oct; 232(10):2657-2673. PubMed ID: 28075018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
    Bradley CA; Salto-Tellez M; Laurent-Puig P; Bardelli A; Rolfo C; Tabernero J; Khawaja HA; Lawler M; Johnston PG; Van Schaeybroeck S;
    Nat Rev Clin Oncol; 2017 Sep; 14(9):562-576. PubMed ID: 28374784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
    Ghanaatgar-Kasbi S; Khorrami S; Avan A; Aledavoud SA; Ferns GA
    Curr Pharm Des; 2018; 24(39):4619-4625. PubMed ID: 30636579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-MET inhibitors in the treatment of lung cancer.
    Goździk-Spychalska J; Szyszka-Barth K; Spychalski L; Ramlau K; Wójtowicz J; Batura-Gabryel H; Ramlau R
    Curr Treat Options Oncol; 2014 Dec; 15(4):670-82. PubMed ID: 25266653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
    Cui JJ
    J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MET signalling pathway and its therapeutic implications in gastrointestinal cancers].
    Zaanan A; Laurent-Puig P; Taieb J
    Bull Cancer; 2014 Jan; 101(1):25-30. PubMed ID: 24445683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
    Koeppen H; Rost S; Yauch RL
    J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
    Yap TA; Sandhu SK; Alam SM; de Bono JS
    Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
    Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
    Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the HGF/Met signalling pathway in cancer.
    Cecchi F; Rabe DC; Bottaro DP
    Eur J Cancer; 2010 May; 46(7):1260-70. PubMed ID: 20303741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
    Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
    Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
    Wang J; Goetsch L; Tucker L; Zhang Q; Gonzalez A; Vaidya KS; Oleksijew A; Boghaert E; Song M; Sokolova I; Pestova E; Anderson M; Pappano WN; Ansell P; Bhathena A; Naumovski L; Corvaia N; Reilly EB
    BMC Cancer; 2016 Feb; 16():105. PubMed ID: 26879245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.